← Back to Search

Immunomodulator

ABX196 for Hepatocellular Carcinoma

Phase 1 & 2

Waitlist Available

Led By Darren SIGAL, MD

Research Sponsored by Abivax S.A.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 1 year

Awards & highlights

Study Summary

This trial is testing a new drug, ABX196, to see if it is safe and effective in treating hepatocellular carcinoma when used with nivolumab.

Eligible Conditions

Hepatocellular Carcinoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence of adverse events (AEs)

Secondary outcome measures

Alpha Fetoprotein Serum concentrations

Duration of Response (DOR)

Objective Response Rate (ORR)

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: ABX196Experimental Treatment1 Intervention

IM injection of 0.1, 0.2, and 0.4 µg of ABX196

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Abivax S.A.Lead Sponsor

20 Previous Clinical Trials

4,217 Total Patients Enrolled

C3 Research AssociatesUNKNOWN

2 Previous Clinical Trials

111 Total Patients Enrolled

Darren SIGAL, MDPrincipal InvestigatorScripps Clinic/Scripps MD Anderson Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this investigation unprecedented in its approach?

"Presently, ABX196 is being trialled at two locations across one nation. The inaugural trial for the drug was conducted in 2019 by Abivax S.A., and involved 48 patients who completed both phases of clinical testing successfully. Since then, no further studies have been concluded."

Answered by AI

What is the current participant count of this clinical experiment?

"Affirmative. According to the clinicaltrials.gov website, this investigation is actively recruiting patients who meet their criteria. This study was first published on August 30th 2019 and has since been modified on March 25th 2021. 48 participants need to be enrolled between two medical sites in order for it to progress further."

Answered by AI

To what extent has ABX196 been tested in prior research?

"Currently, there is only one active clinical trial researching ABX196 with no Phase 3 trials in effect. Most of the research for this drug is taking place at Houston, Texas though two other sites are also running relevant tests."

Answered by AI

Are there any opportunities for volunteers to join this research project?

"According to clinicaltrials.gov, this research is seeking participants at the moment; it was initially advertised on August 30th 2019 and recently revisited on March 25 2021."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma

2019. "ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03897543.

All > Hcc > Hepatocellular Carcinoma